Walter Klemp V - 20 Jun 2024 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role: CEO and President, Director
Signature: /s/ Jonathan P. Foster by Power of Attorney
Issuer symbol: MBRX
Transactions as of: 20 Jun 2024
Net transactions value: -$3,455
Form type: 4
Filing time: 21 Jun 2024, 17:00:55 UTC
Previous filing: 18 Jun 2024
Next filing: 24 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBRX	Common Stock	Options Exercise		+3,750	+8%		50,407	20 Jun 2024	Direct	F1
transaction	MBRX	Common Stock	Tax liability	$3,455	-914	-1.8%	$3.78	49,493	20 Jun 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBRX	Restricted Stock Units	Options Exercise	$0	-3,750	-3%	$0.000000	123,124	20 Jun 2024	Common Stock	3,750		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3	On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.